Cometriq · Oncology · revenue 2200 Cometriq blocks the VEGFR2 pathway to prevent tumor growth and angiogenesis.
Cometriq · Oncology Cometriq works by blocking the activity of vascular endothelial growth factor receptor 2, a protein involved in tumor growth and angiogenesis.
Phase 3 pipeline
Cabozantinib tablets · Oncology Cabozantinib is a multi-targeted tyrosine kinase inhibitor that blocks MET, VEGFR2, and AXL signaling to inhibit tumor growth and angiogenesis.
Everolimus (Afinitor) tablets · Oncology Everolimus inhibits mTOR (mammalian target of rapamycin), a protein kinase that controls cell growth and proliferation.
XL184 · Oncology XL184 is a multi-targeted tyrosine kinase inhibitor that blocks MET, VEGFR2, and RET signaling to inhibit tumor growth and angiogenesis.